Compare Avient Corporation (AVNT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Incyte Corporation — how do they compare? Avient Corporation trades at $45.3 (market cap $4.17B), while Incyte Corporation trades at $120.83 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 5.9× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AVNT | INCY | |
|---|---|---|
Market Cap | $4.17B | $24.54B |
Sector | Technology | Health |
52-Week High | $45.69 | $129.93 |
52-Week Low | $27.48 | $81.61 |
Enterprise Value | $5.62B | $20.04B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $45.1, down 1.2% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue remains stable at $3.3 billion, with a net income margin improving to 5.1% in 2026. Analysts maintain a Buy consensus with a $49 price target, reflecting optimism about continued growth and dividend stability.
The stock offers upside potential from earnings momentum and a solid dividend yield, but faces risks from macroeconomic pressures on materials demand and high RSI levels suggesting overbought conditions. Institutional sentiment is positive, with no Sell ratings, though investors should monitor debt levels and competitive dynamics in the chemical sector for sustained performance.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
